This month, I stepped down as Verily’s Chief Scientific Officer and joined GRAIL, a startup focused on the early detection of cancer, to guide its precision medicine and translational science efforts. I’ll still be affiliated with Verily through its Science Board, which I’ll chair. I write about the reasons for my decision here: Seeing deeply […]